NASDAQ: AVLN · Life Sciences · 4 alerts · CIK 1540171
Share price
$29.76Close, Nov 16
Market cap
$1.32B
Shares outstanding
44.33MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Avalyn Pharma Inc. filings on SEC EDGAR ↗
Avalyn Pharma 10% Owner Fmr LLC Sells $6.7M of Stock
Fmr LLC, 10% Owner, sold 228,454 shares of Avalyn Pharma Inc. at $29.06 to $30.28 a share (average $29.33) in 4 transactions, worth $6.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,056,081 (-2.3%).
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.
Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.
Term
Q3 2026
“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”
Lyn Baranowski, Chief Executive Officer of Avalyn
“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”